Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1056_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •About the Editors
- •Contributors
- •3 Host Factors: Age, Gender, Lifestyle
- •4 IBD and Other Etiologically Relevant Comorbid Conditions
- •5 Anatomical Presentation and Rectovaginal Fistula
- •6 Anal Fistula Development: Microbiological Factors
- •7 Recurrence and Cancer Risk
- •8 Conclusion
- •References
- •1 Epidemiology of Anal Fistula and Abscess
- •1 Introduction
- •2 Incidence and Prevalence
- •2.1 Europe
- •2.2 USA and Canada
- •2 Anorectal Anatomy Related to Anal Fistula and Abscess
- •1 Introduction
- •2 Mucosal Layer and Submucosal Space
- •3 Internal Anal Sphincter
- •4 Intersphincteric Space and Conjoint Longitudinal Muscle
- •5 External Anal Sphincter
- •6 Pelvic Floor
- •7 Extra-anal Spaces/Ischioanal Fossae
- •8 Anal Glands
- •10 Conclusion
- •11 Cross-References
- •References
- •3 Anorectal Physiology Related to Anal Fistula and Abscess
- •1 Principal Aspects of Anorectal Physiology
- •1.1 Secretory Function of the Anorectum and the Cryptoglandular Hypothesis
- •1.2 Histology and Cellular Physiology of the Anorectum and Fistula
- •1.3 Microbiology and Fistula
- •1.4 Host Factors Relevant to Abscess and Fistula
- •1.5 Anal Continence
- •1.5.1 The Rectum
- •1.5.2 The Musculature of the Pelvic Floor and Sphincter Complex
- •1.6 Defecation
- •1.7 Anorectal Physiology Testing in the Context of Fistula
- •1.7.2 Perioperative Anorectal Physiology Testing
- •2 Conclusion
- •References
- •4 Unconventional Insights in the Pathogenesis and Etiology of Fistulas in the Perianal Region
- •1 Introduction
- •1.1 Etiology
- •1.2 Risk Factors for Development of Perianal Fistula
- •1.3 Risk Factors due to the Type of Perianal Fistula
- •1.4 Treatment-Related Risk Factors for Failure
- •1.5 Preliminary Conclusions
- •2.1 Anatomy of the Anal Canal
- •2.2 Histology of the Anal Canal
- •2.3 Histopathologic Concepts of Perianal Fistulas
- •3.1 Old Stories, New Histopathological Concepts?
- •3.2 Old Stories, New Clinical Concepts?
- •3.2.1 Basic Concepts
- •3.3 Based on Previous Medical History
- •3.4 Aspect and Localization of the Fistula Opening
- •3.5 Phenotype 1
- •3.6 Phenotype 2
- •3.7 Phenotype 3
- •3.8 Phenotype 4
- •3.9 Phenotype 5
- •4 Discussion and Conclusions
- •5 Cross-References
- •References
- •5 From Abscess to Fistula
- •1 Anorectal Abscess
- •References
- •6 Classification of Anal Fistula and Abscess
- •1 Introduction
- •2 Purpose and Attributes of a Classification
- •3 Overview of Anal Fistula Classifications
- •4 Anal Fistula Classifications
- •4.1 Parks Classification
- •4.1.1 Strong Points
- •4.1.2 Weak Points
- •5.1 Strong Points
- •5.2 Weak Points
- •6 Garg Classification
- •6.6 Strong Points
- •6.7 Weak Points
- •7 Status of Extrasphincteric Fistulas
- •8 Evaluation of Existing Classifications on Long-Term Data
- •9 Conclusions
- •References
- •7 Clinical Assessment of Anal Cryptoglandular Abscess and Fistula
- •1 Introduction
- •2 Types of Clinical Evaluation
- •3 Diagnosis
- •4 Topographic Evaluation
- •4.1 The Cryptic Endoanal Primary Opening
- •4.2 The Secondary Opening or Openings
- •4.3 The Main Tract of the Fistula
- •4.4 Possible Purulent Collections
- •1.1 Physical Examination of the Anus and Rectum: General Principles
- •4.5 Possible Secondary Extensions
- •5 Conclusion
- •References
- •8 Clinical Assessment of Crohn Perianal Abscesses and Fistulas
- •1 Introduction
- •1.2 Inspection
- •1.3 Palpation
- •1.4 Endoscopy
- •2 Clinical Presentation
- •2.1 Skin Lesions
- •2.2 Fistulas
- •2.3 Abscesses
- •2.4 Diagnostic Workup
- •2.4.1 General Principles
- •2.5 US
- •2.6 Effectiveness and Sensitivity
- •2.6.1 Endoscopy
- •2.7 MRI
- •2.7.1 CT Scan
- •2.7.2 Fistulography
- •2.8 Diagnostic Follow-up
- •References
- •9 Anorectal Physiology Assessment in Patients with Anal Fistula: When Necessary
- •1 Introduction
- •2 Anorectal Physiology Assessment
- •2.1 Anamnesis
- •2.2 Physical Examination
- •2.3 Anorectal Manometry
- •2.3.1 Equipment
- •2.3.2 Manometry Systems
- •2.4 Neurophysiologic Tests
- •2.4.1 Electromyography
- •2.4.2 Nerve Conduction Studies
- •2.5 Endoanal Ultrasound
- •2.6 Role of Anorectal Physiology Patterns in the Decision-Making
- •3 Discussion
- •References
- •1 Introduction
- •2 Anal Anatomy
- •3 Classification of Fistulas
- •4 EAUS Imaging
- •4.1 Probes EAUS
- •4.2 Performing EAUS
- •4.3 EUS in Perianal Fistulas
- •4.4 Adding Hydrogen Peroxide (H2O2)
- •4.5 Cryptoglandular Fistulas
- •5 Comparison with Other Diagnostic Modalities
- •5.1 Comparison with Surgery
- •5.2 Comparison with MRI
- •5.3 Perineal Ultrasound
- •6 Conclusion and Recommendation
- •References
- •1 Introduction
- •2 Imaging
- •2.1 Conventional Contrast Material-Enhanced Fistulography
- •2.2 CT
- •2.3 Magnetic Resonance Imaging
- •2.3.1 Anatomy MRI
- •2.3.2 MRI Technique (Coils, Volume, and Sequences) and Findings
- •2.3.3 MRI Reconstruction Techniques and Fistulography MRI
- •2.3.4 Internal and Cutaneous Opening
- •2.3.5 Classifications of Perianal Fistulas and Abscesses
- •2.3.6 Deep Posterior Anal Fistulas and Abscess
- •2.3.7 MRI Report
- •2.3.9 MR Role in the Evaluation of the Crypto-Glandular Fistulas
- •3 Conclusion
- •4 Cross-References
- •References
- •1 Introduction
- •2 Clinical Presentation
- •3 Utility and Limitations of Endoanal Ultrasound
- •4 Conclusion
- •5 Cross-References
- •References
- •1 Introduction
- •2 Imaging
- •3 Diagnosis
- •4 MRI Technique
- •5 Disease Monitoring
- •6 Future Directions
- •7 Conclusion
- •8 Cross-References
- •References
- •14 Future Perspectives in the Diagnosis of Anal Fistula and Abscess
- •1 Introduction
- •2 Assessment of Abscess and Anal Fistula
- •3 Abscess
- •3.1 Computed Tomography (CT)
- •3.2 Magnetic Resonance Imaging (MRI)
- •3.3 Endoanal Ultrasound
- •3.4 Transperineal Ultrasonography (TP-US)
- •4 Anal Fistula
- •4.1 Imaging
- •4.1.1 Endoanal Ultrasound
- •4.1.2 Magnetic Resonance Imaging
- •5 Conclusion
- •6 Cross-References
- •References
- •15 How to Drain an Abscess
- •1 Introduction
- •2 Epidemiology and Etiology
- •3 Classification
- •4 Clinical Manifestations and Diagnosis
- •5 Management
- •7 Wound Dressing
- •8 Microbiology and Antibiotics
- •9 General Postoperative Management
- •10 Conclusion
- •11 Cross-References
- •References
- •16 The Seton in Anal Fistula Management
- •1 Introduction
- •2 2500 Years of Setons
- •3 To Put or Not to Put
- •4 To Cut or Not to Cut
- •5 What Kind of Seton to Use?
- •7 Seton 2.0: New Perspectives
- •8 Uncomfortable Questions (How to Do It)
- •9 What Patients Should Know
- •10 Conclusions: Seton in Guidelines
- •References
- •17 Fistulotomy
- •1 Introduction
- •2 Indications
- •3 Fistulotomy: Standard Technique
- •4 Other Fistulotomy Techniques
- •4.1 Addition of Loose Seton
- •4.2 Slow Dissection of the Sphincter: Cutting Seton
- •4.3 Addition of Marsupialization
- •5 Fistulotomy with Immediate Primary Sphincteroplasty (FIPS)
- •7 Postoperative Care
- •8 Complications and Recurrence Rate
- •9 Discussion
- •10 Conclusion
- •References
- •18 Fistulectomy
- •1 Introduction
- •2 Preoperative Evaluation
- •2.1 Patient Selection
- •2.2 Imaging
- •2.3 Physiologic Testing
- •2.4 Endoscopic Examination
- •3 Technique
- •3.1 Patient Preparation
- •3.2 Patient Positioning
- •3.2.1 Technical Steps
- •4 Postoperative Care
- •5 Results
- •5.1 Fistulectomy
- •6 Fistulectomy with Sphincter Reconstruction
- •7 Conclusions
- •References
- •19 Utility of Adding Sphincter Reconstruction to Fistulotomy/Fistulectomy
- •1 Introduction
- •2 General Classification
- •3 Preoperative Preparation
- •4 Surgical Technique Step by Step
- •5 Results
- •6 Conclusion
- •7 Cross-References
- •References
- •20 Utility of Marsupialization Following Anal Fistula Surgery
- •1 Introduction
- •2 Marsupialization
- •3 Clinical Evidence
- •4 Conclusion
- •References
- •21 Transanal Advancement Flap Repair
- •1 Introduction
- •2 Nomenclature
- •3 Effectiveness of the Technique
- •4 Effectiveness of Repeat Procedures
- •5 Impact on Fecal Continence
- •6 Severity of Incontinence
- •7 Perioperative Care
- •7.1 Bowel Preparation
- •7.2 Antibiotic Prophylaxis
- •7.3 Prolonged Antibiotic Therapy
- •7.4 Type of Anesthesia
- •7.5 Immobilization
- •7.6 Bowel Confinement
- •7.7 Stool Softeners
- •7.8 Position
- •8 Aspects of Surgical Technique
- •8.1 Preoperative Care
- •8.2 Step 1
- •8.3 Step 2
- •8.4 Step 3
- •8.5 Step 4
- •8.6 Step 5
- •8.7 Postoperative Care
- •8.8 Types of Flap
- •8.9 Shape of Flap
- •8.10 Thickness of Flap
- •8.11 Addition of Accessory Techniques
- •9 Necessity of Preoperative Imaging
- •10 Factors Contributing to Successful Healing
- •10.1 Fistula-Related Factors
- •10.2 Patient-Related Factors
- •10.3 Influence of Covering Ostomy
- •10.4 Impact of the Use of Draining Setons
- •11 Conclusion
- •References
- •22 Dermal Flap Anoplasty for Trans-sphincteric Anal Fistula
- •1 Rationale
- •2 Technique
- •3 Other Dermal Flaps
- •4 Discussion
- •5 Cross-References
- •References
- •23 (LIFT) Ligation of Intersphincteric Fistula Tract
- •References
- •24 Anal Fistula: Glue and Paste Injection
- •1 Introduction
- •2 Fibrin Glue
- •3 Collagen Paste
- •4 Conclusion
- •5 Cross-References
- •References
- •25 VAAFT
- •1 Introduction
- •1.1 VAAFT Story
- •2 Surgical Equipment and Accessories
- •3 VAAFT Indications
- •3.1 Preoperative Assessment
- •4 VAAFT Procedure
- •4.1 Diagnostic Phase (Fistuloscopy)
- •4.2 Operative Phase
- •5 Closure of the Internal Opening
- •5.1 Use of a Linear or Semicircular Stapler
- •5.2 Advancement Flap
- •5.3 Use of a Bioabsorbable Mesh (Xenograft)
- •5.4 Autologous Dermis Graft
- •5.4.1 VAAFT Associated to the LIFT Procedure
- •5.5 Postoperative Management
- •6 Discussion
- •7 Conclusions
- •References
- •26 The Laser Treatment of Anal Fistulas
- •1 Introduction
- •1.1 Literature Review
- •1.3 Diagnosis and Treatment of Complex Anal Fistulas
- •2 Materials and Methods
- •3 Conclusion
- •References
- •27 Treatment by Over-the-Scope-Clip
- •1 Introduction
- •2 Technical Background
- •3 Surgical Application
- •4 Principle of Action
- •5 Clinical Data
- •References
- •28 Stem Cells in Cryptoglandular Anal Fistulas
- •1 Introduction
- •2 History of a Novel Approach
- •2.1 Mesenchymal Stem Cells
- •2.2 Adipose Tissue: The Ideal MSCs Source
- •2.3 Adipose Tissue Graft
- •2.3.1 Lipogems
- •3 Results
- •3.1 Literature Review
- •3.2 Personal Experience
- •4 Discussion and Conclusion
- •References
- •1 Introduction
- •2 Perianal and Rectovaginal Fistulas
- •2.1 Epidemiology and Diagnosis
- •2.2 Classification
- •2.3 Treatment Modalities
- •3 Flap Reconstruction
- •3.1 Overview and Considerations for Flap Reconstruction
- •4 Gracilis Interposition Flap
- •4.1 Background and Indications
- •4.2 Operative Technique
- •4.3 Results/Complications
- •5 Martius Interposition Flap
- •5.1 History and Indications
- •5.2 Surgical Technique
- •5.3 Results/Complications
- •6 Gluteal Muscle Interposition Flap
- •6.1 History and Indications
- •6.2 Surgical Technique
- •6.3 Results/Complications
- •7 Conclusion
- •References
- •30 Quality of Life Following Anal Fistula Treatment
- •1 Introduction
- •2 Quality of Life with an Anal Fistula
- •2.1 Cryptoglandular Fistulas
- •2.3 Conclusion
- •3 Quality of Life with a Seton and a Fistula

458 G. Naldini et al.
• Microfragmentation and simultaneous elimination of oily and bloody residual.
• Aspiration of the activated final product ready to be injected.
The great advantage brought by the Lipogems
®
system is to provide transplantable clusters of lipoaspirate improving their engraftment. It is not a cell transplant but
rather a tissue graft containing activated MSCs inside adipose clusters. Moreover,
the importance of thickness of the tissue and its clusters to achieve an optimal
engraftment is well known and defined through the experiences in skin grafting
(Bianchi et al. 2013).
Comparing the final product obtained after Lipogems
lipoaspirate, it was evident at the histological findings that Lipogems
®
process with the common
®
samples
maintained a better vascular stroma composed by slit-like capillaries and stromal
stalks containing evident lumina of vascular channels; on the contrary, convent ional
lipoaspirate had compressed and distorted microchannels. In addition, CD146
expression, which is coexpressed by endothelial cells and pericytes, was significantly increased in the Lipogems
®
samples (Bianchi et al. 2013) and revealed also to
have a long-lasting anti-inflammatory activity probably sustained by a long-term
survival of their MSCs (Nava et al. 2019).
3 Results
3.1 Literature Review
Only few studies investigated the outcomes of adipose-derived MSCs for the
treatment of complex cryptoglandular fistulas. The results with literature review
are resumed in Table 1.
Garcia-Olmo et al. published a phase II clinical trial in 2009 (Garcia-Olmo et al.
2009) on 49 patients, but only 35 were affected by cryptoglandular fistula. They
were treated with the closure of internal orifice (IO) in association with injection of
autologous adipose-derived stem cells, ASCs, along with fibrin glue (Group I) or
only fibrin glue (Group II). At least 2 weeks prior to therapy administration, all
patients underwent liposuction for manufacturing of ASCs to be used during the
study or for cryopreservation in Group II. The reported healing rate for the two
groups I-II at 1-year follow-up was 71% and 16%, respectively.
Guadalajara et al. reported in 2012 (Guadalajara et al. 2012) a low success rate
of the group ASCs with fibrin glue which was 57.1% (lower than 71% previously
reported). The group treated with fibrin glue only had 20% success rate (slightly
higher than 16% previously published). These outcomes were at the end of
the treatment including the first and second procedure to close complex
cryptoglandular fistulas.
Herreros et al. published a Randomized Clinical Trial (RCT) in 2012 (Herreros
et al. 2012) with 200 patients enrolled. They were subdivided into three groups:
Group A treated with the only ASCs injection, Group B treated with ASCs
injection in associat ion with fibrin glue, and Group C treated only with fibrin

28 Stem Cells in Cryptoglandular Anal Fistulas 459
(continued)
adverse events
considered related
to the treatment
(purulent
secretion, rectal
bleeding, and
pyrexia)
adverse events
Follow-up
(range) Complications
12 Not reported
71%
16%
ASC +
Fibrin
glue
Fibrin
glue
48 Total of 8.1% had
57.1%
20%
ASC +
Fibrin
These are at
glue
the end of
treatment
Fibrin
glue
including the
second
procedure
12 No serious
Group A
57.1%,
Group A
ASC
Group B
Group B
52.4%
Group C
ASC +
Fibrin
37.3%
glue
Group C
fibrin glue
/// 57.1% 46 Not reported
Table 1 Literature review
Age
Two steps
mean M:F Technique Subgroups Healing rate
35
Phase II
Author, year Study design N of patients
Garcia-
ASC+
IO closure
Total 49
14 CD
clinical trial
Olmo et al.
(2009)
8:13
7:6
41
40
1410Considering only
cryptoglandular
Phase II
clinical trial
Guadalajara
et al. (2012)
Two steps
ASC+
IO closure
A
47:17B36:24C44:15
B 47.2
C 50.8
RCT phase III 200 A 49.7
Herreros
et al. (2012)
Cellution
system +
IO closure
42.3 5:2 One step
7
Two had preop.
Colostomy
Observational
study
Borowski
et al. (2015)

460 G. Naldini et al.
abdominal wall
hematoma, One
Follow-up
(range) Complications
9(3–12) Three minor
Overall 73.7%
Group I
Group I 83.3%
Group II
First time
group
perianal abscess
57.1%
Group II
Recurrent
reactions or
20 (6–48) No adverse
Improvement
91.6%
group
SVF 60%
(31/52)
complications
Healing 50%
SVF 69.2%
Au- eASC
16%
Au- eASC
17%
(9/52)
Allo-
Allo-eASC
40%
eASC
23%
(12/52)
adverse events.
6 No serious
complete
/// 3 (20%)
One plug
extrusion, One
healing
8 (53.3%)
abdominal wall
partial healing
Age
mean M:F Technique Subgroups Healing rate
Author, year Study design N of patients
Table 1 (continued)
Lipogems
device +
19 48 7:12 One step
Pilot
observational
study
Naldini et al.
(2018)
IO closure
Cellution
system+
IO closure
24:21 One step
24
Cryptoglandular
Total
52 procedures for
Observational
study
Herreros
et al. (2019)
SVF
2 steps
45 patients
18 CD
Au- eASC+IO closure
Allo-
3RVF
eASC+
IO closure
In the
32/52
case,
fibrin glue
Was used
15 39.8 7:8 Two steps
Phase I
Dozois et al.
MSC-
MATRIX
clinical trial
(2019)

28 Stem Cells in Cryptoglandular Anal Fistulas 461
seroma, And three
perianal abscesses
Eleven AEs in
seven patients of
group A
16 events among
24
Group A 50%
Group A
Only
39 pts.
(10/20)
Group B
ASC +
Fibrin
9 patients in groupBNone of the AEs
completed
the follow-
26.3%
(5/19)
glue
Group B
up
Fibrin
glue
were related to the
treatment
Two steps
ASC+
A
16:7B14:7
A 50.1
B 50.8
Total of
56 patients out of
Phase III
clinical trial
Garcia-
Arranz et al.
IO closure
the 57 subjects
enrolled, 44 were
(2020)
randomized (ITT
population), and
39 underwent
follow-up (PP)
SVF Stromal Vascular Fraction, Au-eASC Autologous expanded adipose-derived stem cells, Allo-eASC Allogenic expanded adipose-derived stem cells, CD
MSC-loaded plug
Crohn’s Disease, RVF Rectovaginal fistula, ASC autologous adipose-derived stem cells, ITT Intention-to-treat, PP per protocol population, MSC-MATRIX

462 G. Naldini et al.
glue and saline solution (placebo) injection. At 1-year follow-up, the healing rate
was as follows: Group A 57.1%, Group B 52.4%, and Group C 37.3%. In each
group, IO was always closed.
Recently in 2020, an RCT was published by Garcia-Arranz et al.(2020) which
takes into account the results of previous phase II clinical trials (Garcia-Olmo et al.
2009; Guadalajara et al. 2012) and tried to correct the study design mistakes of the
FATT-1 trial (Herreros et al. 2012). It is a multicenter, randomized, single-blind
clinical trial that enrolled 57 patients. Forty-four were included into the inte nt-totreat group and divided into two subgroups: Group A was treated with ASCs
associated with intralesional fibrin glue injection, and Group B received only
intralesional fibrin glue. In both cases, partial fistulectomy and closure of IO
was always performed. The patients not healed after 16 weeks were eligible
for retreatment. At 24 months follow-up, the healing rate was 50.0% in Group
A and 26.3% in Group B. These results essentially confirmed what was
previously reported.
Borowski et al. (2015) reported a personal experience on 7 patients with
recurrent complex cryptoglandular fi stula-in-ano. All of them received one or
more treatments prior to be enrolled in the study. Two of them had a colostomy to
manage the perianal sepsis, and it was closed after fistula healing. In this series,
the technique used was different, and it was based on a single-step procedure
using Celution 800/CRS system (Cytori Therapeutics Inc., San Diego, CA, USA)
which generates the SVF that is the precursor of MSCs, derived from liposuction.
The automated Celution process takes a total time of approximately 90–120 min,
and it is based on enzymatic digestion. At 46 months of follow-up, the healing
rate was 57.1%.
Naldini et al. (2018) published a pilot observational study including only
19 patients who were eligible according to the strict including criteria. The patients
were divided into 2 groups: Group I in which it is the first sphincter saving
procedure, and Group II including those who had failed prior sphincter-saving
procedures. The procedure was based on IO closure associated with autologous
microfragmented adipose tissue injection obtained through Lipogems
®
system. The
overall healing rate was 73.7–83.3% and 57.1%, respectively, for Group I and Group
II. The procedure resulted to be safe, feasible, and reproducible enhancing complex
anal fistula healing.
Herreros et al. published in 2018 a compassionate use stem cell injection
associated to the closure of IO through a flap for complex perianal fistulas of
patients who were not eligible for the previous reported RCT (Herreros et al.
2019).Itisanobservationalstudyinwhichonly24upto45patientshada
cryptoglandular fistula. It is fairly heterogeneous because three different procedureswereusedtogetthefinal product: autologous expanded adipose-derived
stem cells (Au- eASC), allogenic expanded adipose-derived stem cells (AlloeASC) which are a two-step procedure, and Celution system (SVF) which is a
single step. At mean follow-up of 40 months, 91.6% had improvement and 50%
complete healing. The success rate stratified according the procedure was SVF
69.2%, Au- eASC 16%, and Allo-eASC 40%.

28 Stem Cells in Cryptoglandular Anal Fistulas 463
At least, Dozois et al. (2019) reported a phase I clinical trial about the use of
autologous mesenchymal stem cell-coated fistula plug in patients with transphincteric cryptoglandular fistulas. It is a two-step procedure based on lipoaspiration and then a creation of the novel bioactive plug. At 6 months follow-up,
three patients (20%) showed a complete healing while eight patients (53.3%) had
only partial healing.
3.2 Personal Experience
From January 2015 to January 2019, 50 patients affected by cryptoglandular complex anal fistula were treated with Micro-fragmented Autologous Adipose Tissue
Injection (MAATI) associated with IO closure using flap. Total 41 belong to Group I
(first line treatment) and 9 to Group II (recurrent disease). The mean follow-up is
35 months (range 64–17) with an overall success rate of 76%, respectively 80.5%
and 55.5% for Group I and II.
In the same interval period, 51 patients with the same characteristics were treated
with conventional advancement flap: 39 belong to Group I (first line treatment) and
12 to Group II (recurrent disease). The mean follow-up is 32 months (range 68–17)
with an overall success rate of 58.8%. Group I and Group II had 61.5% and 50%,
respectively.
The authors in the present series used very strict selection criteria excluding all
the conditions that could add bias to the final results interpretation trying to check the
real effectiveness of MAATI. The exclusion criteria were the following: multiple
fistula tracts, acute abscess, inflammatory bowel disease, HIV, HBV or HCV infection, rectovaginal fistula, personal therapy with anticoagulants, steroids or
immunomodulants, anamnesis of pelvic radiotherapy, history of neoplasia within
5 years from the diagnosis, pregnancy, uncontrolled diabetes, coagulopathy, or
connective tissue diseases. Only single track cryptoglandular complex anal fistulas
confirmed by pelvic magnetic resonance or three-dimensional 360
sound were enrolled.
Comparing the results reported would seem that MAATI contributes to the fistula
closure, showing its maximal effectiveness in those patients who were treated for the
first time with sphincter-saving procedu re just after seton placement (around 4–
6 weeks) to drain the acute phase.
transanal ultra-
4 Discussion and Conclusion
Anal fistula is a rare proctologic condition according to European Medicines Agency
(“European Medicines Agency, Committee for Orphan Medicinal Products.
Alofisel—Orphan Maintenance Assessment Report. Accessed 10.2019,” 2018)
whose treatment represents one of the most challenging procedures for proctologists
because of the high rate of recurrence (Amato et al. 2020).

464 G. Naldini et al.
Moreover, the postoperative impaired anal continence rate may be not negligible,
and it raises up to 53% after laying open an intersphincteric or transphincteric fistula
(Lunniss et al. 1994).
This background has led to a growing number of innovative procedures to treat
complex anal fistula trying to preserve the sphincters and their function. Among
these, one of the latest techniques proposed is based on the well-known regenerative
effect of the injection of MSCs.
Differently for other application fields, for complex anal fistulas it was always
associated to the combined treatment of internal orifice. In fact, IO may be considered as the turning point to maintain a chronic inflammation thus preventing the
spontaneous fistula closure.
In all the studies conducted by Garcia-Olmo and collaborators, they frequently
use the fibrin glue associated to the MSCs injection and IO closure. The reason in
this case is to give to these cells a scaffold upon which they can proliferate. Their
healing rate ranged between 50% and 60% reaching a peak of 69.2% in that group
treated with the SVF obtained through the Celurion system (Herreros et al. 2012).
On the opposite, Naldini et al. used a novel device (Lipogems
®
) which allows a
tissue graft. In this way, they get a double advantage. In fact, if on the one hand the
one-step procedure reduces operative times, costs, and patients’ psycho-physical
involvement, on the other, it facilitates the surgeon to bypass the GMP restrictions
guaranteeing a final product which already contains MSCs with their scaffold. It
does not need additives to facilitate the engraftment resulting to be a safe, feasible,
and reproducible technique.
Interestingly, IO closure is not a conventional treatment strategy in Crohn-related
anal fistula where Laureti et al. (2020) recently reported 93.3% clin ical remission
with absence of drainage upon gentle finger compression on the external orifice
while 66.7% presented combined (clinical and radiological) remission at 6 months
postoperative follow-up. Almost half of the pati ents were administered with pharmacological agents during the study. Surely, CD opens a different pathogenic field in
which a relevant role is played by the disease activity; however, these are really
promising results. They used the same one-step device (Lipogems
®
) used by Naldini
et al. (2018) for cryptoglandular complex fistulas in which the overall healing rate
was 73.7%. In this series, anyhow, the IO was always closed with advancement flap.
A possible bias of all the studies conducted on complex cryptogland ular fistulas is
the difficulty to clearly differentiate the contribution of the IO closure and the MSCs
injection. However, considering the average advancement flap success rate of 66.7%
(range 20–100%) (Kontovounisios et al. 2016), a contribution seems to be evident
from the series of Naldini differently from the series of Garcia-Olmo and collaborators. These might be explained with the different surgical steps and devices used,
focusing on the differences of MSCs plus fibrin glue injection instead of adipose
tissue graft.
In the series of Dozois et al., instead, a further novel technique was reported in
which they associate MSCs with plug placement. Although the follow-up is short,
the results seem not so promising and this follows the published literature about plug
surgery and its healing rates.

28 Stem Cells in Cryptoglandular Anal Fistulas 465
Unfortunately, there are no clear guidelines for MSCs use in surgical fields. In
particular, for digestive tract whose diseases are generally well localized, the
suggested application of MSCs is through a local injection (instead of systemic
use as for systemic diseases) thus minimizing the side-effects keeping MSCs directly
in contact with the injured tissue. Moreover, there is no consensus about the
procedure and its surgical steps as how to inject the cells (needle size, speed,
concentration, and volume amount) to achieve the maximal beneficial effect
(Georgiev-Hristov et al. 2018).
In addition, in the tissue graft therapy, the exact cell concentration contained inside
the harvested and prepared final product is not known, and it may probably vary from
patient and adipose tissue features. This limit is also related to the undefined amount of
final product needed to be injected to get an effective result. According to the authors’
experience, it should not be less than 12 cc because of almost 4–6 cc around the IO and
6–8 cc along the fistula tract. Conversely, in the cell-based therapy prepared in the
laboratory, cell concentration is well defined (usually 5 million cells/ml) and delivered
in vials whose volume is known. Although the preoperative MSCs parameters should
be defined to achieve a reproducible procedure, the two techniques have substantial
differences (mainly the knowledge of MSCs amount injected) which would not seem
directly related to the final outcome.
However, a concept that needs to underline this tissue/cellular-based therapy is
that they cannot be considered as filler agents. They should be injected neither inside
the fistula tract as for other biomaterials (Fabiani et al. 2017) because the cells will
probably be lost very early with the postoperative secretions, nor too far from the
fistula walls thus preventing their contribution to the fistula closure. MSCs need to be
injected around the IO and along all the fistula length to exploit their biologic activity
promoting reparative mechanism for tissue regeneration and reducing the inflammation. Furthermore, the uniform distribution of the product injected may be influenced
by the presence of a fibrotic tissue which is fairly frequent in chronic fistulas
whereby a slow and careful injection is required in such cases.
An important limitation of the autologous tissue injection is the real availability of
“good” fat tissue to be easily harvested. Very thin patients, frequently those affected
by CD but not only, are not suitable for these procedures, and in these cases the
authors suggest to harvest fat tissue directly from the trochanteric regions if feasible.
It is possible to harvest the tissue from these regions just after anterior abdom inal
wall harvesting (in these cases, it is recommended to infiltrate with not more of
120 cc modified Klein solution to avoid to get only fluid instead of fat tissue). In case
of preoperative plan to harvest only from both trochanteric regions (it is important to
maintain symmetry as also for the abdominal wall), the patient needs to be placed on
lateral position and turned from the left to the right side during the operation. This
procedure requires longer operative time and a well-trained nurse team.
Another issue, not so frequently debated, is the liposuction surgical step. Since the
first case of lipo-aspiration was described by Illouz in 1983 (Illouz 1983), it became
the most spread cosmetic procedure all over the world. The common perception of
lipo-aspiration as a minor cosmetic procedure seems to underestimate the likelihood of
major complications (Barillo et al. 1998;Zakineetal.2015). Indeed, the increase of

466 G. Naldini et al.
the number of procedures was linked to the complications occurrence and its rate
increase. They range from minor complications such as seroma, edema, hematoma
with minor bleeding, and local pain to more important, even life-threatening, complications as pulmonary embolism, pneumothorax, and bowel perforation, occurring also
in death in rare cases. There are some conditions considered as risk factors: thin
abdominal wall, diastasis of the rectus abdominis muscles, abdominal distension that
increases the abdominal convexity, umbilical or ventral hernia especially in those
overweight patients in which they may be clinically misdiagnosed, and history of
abdominal surgery with fixed scar. To prevent complications, the authors learned the
lesson from plastic surgeons (Taha and Tahseen 2020; Zakine et al. 2015)and
accurately evaluated the abdomen with physical examination to detect hernias or
wall weakness. In case of risk factors, a preoperative abdominal ultrasound is
performed. In addition, the procedure is performed carefully harvesting fat tissue
from the superficial and deep subcutaneous fat without abrupt gestures always
checking the cannula orientation and its tip. At last, patients are evaluated 3–5h
after the procedure maintaining the compressive bandage and then reexamined on the
first postoperative day before the discharge just after bandage removal. The only few
cases of minor abdominal wall hematoma occurred in the authors’ series and were
treated conservatively with topical eparine-like ointment administration. Hence, lipoaspiration is an easy and fairly fast procedure to collect the amount of adipose tissue
necessary to perform the surgical procedure for anal fistula, but it needs to be carried
out with care being aware of possible consequences so that they can be prevented and
eventually early identified and treated.
In conclusion, MSCs certainly represent the future of regenerative medicine and
surgery with their several application fields among which one is represented by
complex anal fistula treatment. Future researches need to better clarify their action
mechanisms, and the differences between the two-step procedure with MSCs associated with an external scaffold and the one-step procedure with adipose tissue graft
might explain the different outcomes.
Besides, it is necessary to identify a low-cost, easily reproducible, safe, and
effective procedure whose results are proved on “classical” cases of cryptoglandular
complex anal fistula. In fact, compassionate or last-chance attempts including
complex or multiple recurrent fistulas do not allow the colo-proctologist community
to draw a final conclusion on the real effect of MSCs to promote fistula healing.
References
Alexander RW (2011) Autologous fat grafts as mesenchymal stromal stem cell source for use in
prolotherapy: a simple technique to acquire lipoaspirants. J Prolother 3(3):680–688
Amato A, Bottini C, De Nardi P, Giamundo P, Lauretta A, Realis Luc A, Piloni V (2020) Evaluation
and management of perianal abscess and anal fistula: SICCR position statement. Tech
Coloproctol 24(2):127–143. https://doi.org/10.1007/s10151-019-02144-1

28 Stem Cells in Cryptoglandular Anal Fistulas 467
Atkin GK, Martins J, Tozer P, Ranchod P, Phillips RKS (2011) For many high anal fistulas, lay open
is still a good option. Tech Coloproctol 15(2):143–150. https://doi.org/10.1007/s10151-011-
0676-6
Barillo DJ, Cancio LC, Kim SH, Shirani KZ, Goodwin CW (1998) Fatal and near-fatal complica-
tions of liposuction. South Med J 91(5):487–492. https://doi.org/10.1097/00007611-
199805000-00018
Bianchi F, Maioli M, Leonardi E, Olivi E, Pasquinelli G, Valente S, ... Ventura C (2013) A new
nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-
like elements by mild mechanical forces from human lipoaspirates. Cell Transplant 22(11):
2063–2077. https://doi.org/10.3727/096368912X657855
Bianco P (2009) The great MSC history review. Cell 2(4):313–319. https://doi.org/10.1016/j.stem.
2008.03.002.Mesenchymal
Borowski DW, Gill TS, Agarwal AK, Tabaqchali MA, Garg DK, Bhaskar PUD (2015) Adipose
tissue-derived regenerative cell-enhanced lipofi lling for treatment of cryptoglandular fistulae-in-
ano: the ALFA technique. Surg Innov 22(6):593– 600. https://doi.org/10.1177/
1553350615572656
Caplan AI (1991) Mesenchymal stem cells. Chem Phys Lett 9:641–650. https://doi.org/10.1016/
0009-2614(70)87009-9
Caplan AI (2017) New MSC: MSCs as pericytes are sentinels and gatekeepers. J Orthop Res 35:
1151–1159. https://doi.org/10.1002/jor.23560
Caplan AI, Dennis JE (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98:
1076–1084. https://doi.org/10.1002/jcb.20886
Cheng F, Huang Z, Li Z (2019) Mesenchymal stem-cell therapy for perianal fistulas in Crohn’s
disease: a systematic review and meta-analysis. Tech Coloproctol 23:613–623. https://doi.org/
10.1007/s10151-019-02024-8
Coleman SR (2006) Structural fat grafting: more than a permanent filler. Plast Reconstr Surg 118
(Suppl 3). https://doi.org/10.1097/01.prs.0000234610.81672.e7
Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, ... Péault B (2008) A perivascular
origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301–313.
https://doi.org/10.1016/j.stem.2008.07.003
da Silva Meirelles L, Caplan AI, Nardi NB (2008) In search of the in vivo identity of mesenchymal
stem cells. Stem Cells 26(9):2287–2299. https://doi.org/10.1634/stemcells.2007-1122
Dozois EJ, Lightner AL, Mathis KL, Chua HK, Kelley SR, Fletcher JG, ... Faubion WA (2019)
Early results of a phase I trial using an adipose-derived mesenchymal stem cell-coated fistula
plug for the treatment of transsphincteric cryptoglandular fistulas. Dis Colon Rectum 62(5):
615–622. https://doi.org/10.1097/DCR.0000000000001333
Estève D, Boulet N, Belles C, Zakaroff-Girard A, Decaunes P, Briot A, ... Galitzky J (2019)
Lobular architecture of human adipose tissue defines the niche and fate of progenitor cells. Nat
Commun 10(1):1–
European Medicines Agency, Committee for Orphan Medicinal Products (2018) Alofisel – Orphan
maintenance assessment report. Accessed 10 2019
Fabiani B, Menconi C, Martellucci J, Giani I, Toniolo G, Naldini G (2017) Permacol™ collagen
paste injection for the treatment of complex anal fistula: 1-year follow-up. Tech Coloproctol
21(3):211–215. https://doi.org/10.1007/s10151-017-1590-3
Friedenstein AJ, Chailakhjan RK, Lalykina KS (1870) The development of fibroblast colonies
in monolayer cultures of Guinea-pig bone marrow and spleen c ells. Cell Tissue Kinet 3:
393–403
Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV (1974) Stromal
cells responsible for transferring the microenvironment of the hemopoietic tissues. Transplan-
tation 17:331–340. https://doi.org/10.1097/00007890-197404000-00001
Friedenstein AJ, Chailakhyan RK, Gerasimov UV (1987) Transplantation in diffusion chambers.
Cell Tissue Kinet 20:263–272
16. https://doi.org/10.1038/s41467-019-09992-3
Соседние файлы в папке Библиотека им академика М.И. Перельмана
